Table 2.
Laboratory findings in First Nations and Non-First Nations patients with nonalcoholic fatty liver disease∗.
| Variable (normal range) |
First Nations Baseline/follow-up |
Non-First Nations Baseline/follow-up |
p value Baseline/follow-up |
|---|---|---|---|
| Duration of follow-up (yrs) | 2.9 ± 3.3 | 2.7 ± 3.1 | 0.731 |
| ALT (<30 U/L) | 81 ± 52/59 ± 41 | 83 ± 109/53 ± 43 | 0.92/0.49 |
| AST (10–32 U/L) | 50 ± 31/43 ± 24 | 58 ± 101/37 ± 22 | 0.66/0.13 |
| ALP (30–120 U/L) | 151 ± 77/136 ± 72 | 114 ± 61/102 ± 59 | 0.0002/0.004 |
| GGT (5–38 U/L) | 119 ± 104/118 ± 119 | 124 ± 177/110 ± 191 | 0.88/0.82 |
| Albumin (33–45 G/L) | 38 ± 3.9/38 ± 4.1 | 40 ± 6.1/40 ± 5.1 | 0.01/0.02 |
| Total bilirubin (3–21 μmol/L) | 9.2 ± 6.4/8.5 ± 5.0 | 13 ± 32/12.3 ± 18 | 0.07/0.02 |
| INR (0.9–1.1) | 1.0 ± 0.1/1.0 ± 0.1 | 1.4 ± 1.5/1.1 ± 0.6 | 0.72/0.57 |
| Platelets (140–440 × 109/L) | 279 ± 80/243 ± 83 | 244 ± 71/239 ± 71 | 0.015/0.78 |
| Creatinine (35–106 μmol/L) | 69 ± 21/70 ± 22 | 77 ± 26/81 ± 46 | 0.164/0.07 |
| Total cholesterol (<5.2 mmol/L) | 5.4 ± 0.9 | 6.9 ± 17 | 0.682 |
| Triglycerides (<1.7 mmol/L) | 3.0 ± 2.2 | 5.2 ± 20 | 0.612 |
| Glucose (3.6–6.0 mmol/L) | 8.2 ± 4.3 | 7.0 ± 7.5 | 0.006 |
∗Results represent mean ± SD.
ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma glutamyltransferase; INR: international normalization ratio.